Verona Pharma Leaders to Showcase Innovations in December
LONDON and RALEIGH, N.C. — Verona Pharma plc (NASDAQ: VRNA) is excited to announce that senior management will take the stage at significant healthcare conferences this December. These events are a prime opportunity for the company to provide an overview of its activities and initiatives focused on chronic respiratory diseases.
Piper Sandler Healthcare Conference
The first event is the Piper Sandler 36th Annual Healthcare Conference, where Verona Pharma’s team will present insights on December 3rd. The presentation is scheduled for 12:00 p.m. ET (5:00 p.m. GMT), and will be held in the heart of New York City. This conference gathers industry leaders and innovators to discuss advancements in healthcare, making it an ideal platform for Verona Pharma.
Key Highlights of the Conference Presentation
Attendees can expect thorough insights into Verona Pharma’s commitment to developing effective treatments for patients affected by chronic respiratory diseases. Specific focus will be on the company's leading product, Ohtuvayre™ (ensifentrine), as well as ongoing research initiatives aimed at enhancing patient care.
Evercore HealthCONx Conference
Following the Piper Sandler event, Verona Pharma will participate in the 7th Annual Evercore HealthCONx Conference on December 4th. This session is set to begin at 3:00 p.m. ET (8:00 p.m. GMT) in Miami. The conference serves as a gathering point for biopharmaceutical professionals to share knowledge and discuss innovations that could transform patient outcomes.
Engagement Opportunities
Both conferences present a valuable chance for investors, analysts, and industry peers to engage with Verona Pharma’s leadership. By attending these events, stakeholders can gain a deeper understanding of the company's strategic direction and innovative pipelines.
Webcast Availability
For those unable to attend in person, Verona Pharma will provide webcasts of each conference presentation. These will be accessible via the Investor Relations section on the company’s website. This initiative ensures that all interested parties can stay informed about the company’s progress and upcoming developments.
About Verona Pharma
Verona Pharma is at the forefront of biopharmaceutical innovation, dedicated to addressing significant unmet medical needs in the treatment of chronic respiratory diseases. Their flagship product, Ohtuvayre™, stands out as the first inhaled therapy that combines bronchodilator and anti-inflammatory effects in a single formula. With potential applications in various conditions such as non-cystic fibrosis bronchiectasis, cystic fibrosis, and asthma, Verona Pharma continues to lead the way in offering groundbreaking solutions for patients. For further inquiries and updates, please reach out to Verona Pharma directly by phone or email.
Frequently Asked Questions
What is the purpose of Verona Pharma's participation in these conferences?
The participation aims to share insights into the company's innovative therapies, particularly for chronic respiratory diseases, and to engage with investors and industry professionals.
When are the scheduled presentations for these conferences?
The presentations are set for December 3rd at the Piper Sandler Conference at 12:00 p.m. ET and December 4th at the Evercore HealthCONx Conference at 3:00 p.m. ET.
How can I access the presentations if I cannot attend?
Both conference presentations will be available via webcast on Verona Pharma's Investor Relations website, ensuring broader accessibility for interested parties.
What is Ohtuvayre™ and its significance?
Ohtuvayre™ (ensifentrine) is Verona Pharma's first product, representing a pivotal advancement in inhaled therapies for chronic respiratory conditions by combining bronchodilator and anti-inflammatory properties.
Who can I contact for more information about Verona Pharma?
For more information, you can contact Verona Pharma's Senior Director of Investor Relations, Victoria Stewart, through their provided phone number or email.
